leucine
Leucine is an α-amino acid used in the biosynthesis of proteins. Leucine is an essential hydrophobic amino acid. It is used in the Leucine may be used some people as a supplement to build muscle. Leucine is also found in fish, meat, and poultry. In the pharmaceutical industry, L-leucine is used for parenteral and enteral nutrition and feeding, and is also used as a flavoring product and tablet lubricant in manufacturing. Leucine is an mTOR activator. It is a dietary amino acid with the capacity to directly stimulate muscle protein synthesis. As a dietary supplement, leucine has been found to slow the degradation of muscle tissue by increasing the synthesis of muscle proteins in aged rats. Long-term leucine supplementation does not increase muscle mass or strength in healthy elderly men. Leucine potently activates the mammalian target of rapamycin kinase that regulates cell growth. Infusion of leucine into the rat brain has been shown to decrease food intake and body weight via activation of the mTOR pathway. — NCATS
Clinical trial activity
67 trials · 68 clinical orgs · 0 marketing orgs
Earliest trial started Oct 1, 1999 (NCT00005889)
Timeline
Indications
Approved for
Studied for
- Aging · Phase 1/Phase 2
- Anemia, Diamond-Blackfan · Phase 2
- Anemia, Hypoplastic, Congenital · Phase 1/Phase 2
- Atrophy · Phase 1/Phase 2
- Constipation · Phase 2
- Depression · Phase 2
- Frail Elderly · Phase 1
- Healthy Volunteers · Phase 1
- Hyperoxaluria · Phase 1/Phase 2
- Liver Cirrhosis · Phase 4
- Major Depressive Disorder · Phase 2
- Metabolic Syndrome · Phase 2
- Muscle Hypotonia · Phase 3
- Non-alcoholic Fatty Liver Disease · Phase 2
- Obesity · Phase 2
- Red-Cell Aplasia, Pure · Phase 2
- Sarcopenia · Phase 2/Phase 3
- Vitamin B 6 Deficiency · Phase 2/Phase 3
Mechanism of action
- leucineSupplementation
leucine supplementation
Chemistry & pharmacology
SMILES
CC(C)C[C@H](N)C(O)=O- Mol. weight
- 131.1729 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLeucine ↗
- NCATSGMW67QNF9C ↗
- ChEMBLCHEMBL291962 ↗
Also known as
- 2-amino-4-methylvaleric acid
- 2-amino-4-methylvaleric acid
- (2s)-2-amino-4-methylpentanoic acid
- (2s)-2-amino-4-methylpentanoic acid
- (2s)-alpha-2-amino-4-methylvaleric acid
- (2s)-alpha-2-amino-4-methylvaleric acid
- (2s)-alpha-leucine
- (2s)-alpha-leucine
- chick pea extractvitamin c, l-leucine, vegetable capsule (hypromellose)
- e641
- e641
- l
- l
- leu
- leu
- leu
- leucine
- leucine
- leucine
- leucine
- leucine
- leucine
- leucine
- leucine
- l-leucin
- l-leucin
- l-leucine
- l-leucine
- l-leucine
- l-leucine
- l-leucine
- l-leuzin
- l-leuzin
- (s)-leucine
- (s)-leucine
- (s)-(+)-leucine
- (s)-(+)-leucine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06580145 | Phase 2 | Sep 30, 2024 | Emory University, National Institute of Mental Health (NIMH) |
| NCT06567665 | N/A | Aug 5, 2024 | University of Nottingham |
| NCT05720390 | N/A | Feb 2, 2023 | University of Adelaide |
| NCT05754125 | N/A | Jan 21, 2023 | University of Toronto |
| NCT05576038 | N/A | Nov 1, 2022 | McMaster University |
| NCT05400733 | N/A | Jun 15, 2022 | Texas A&M University |
| NCT05394155 | N/A | Apr 29, 2022 | Canadian Institutes of Health Research (CIHR), University of Toronto |
| NCT05251207 | N/A | Feb 7, 2022 | Poznan University |
| NCT06121869 | N/A | May 7, 2021 | Lindenwood University |
| NCT04702087 | N/A | Jan 22, 2021 | Abiogen Pharma, Fondazione Casemiro Mondino, University of Pavia |
| NCT04247048 | N/A | Jul 31, 2020 | University of Nantes |
| NCT03952884 | N/A | May 3, 2019 | University of Illinois |
| NCT03831399 | Phase 1 | Feb 1, 2019 | Armonea Group, Bonusan BV, University of Valencia |
| NCT03785951 | N/A | Dec 31, 2018 | Barnham Benevolent Foundation, Jason and Daphne Mermikides Charitable Trust, University of Reading |
| NCT03668548 | N/A | Aug 20, 2018 | St Mary's University College, University of Gloucestershire |
| NCT03557684 | Early Phase 1 (Phase 1) | Aug 1, 2018 | National Institute of Mental Health (NIMH), University of California, Los Angeles |
| NCT03506126 | N/A | Apr 17, 2018 | Canadian Institutes of Health Research (CIHR), University of Toronto |
| NCT03364335 | Phase 2 | Jan 8, 2018 | NuSirt Biopharma |
| NCT03197402 | N/A | Nov 1, 2017 | McMaster University |
| NCT05120011 | N/A | Sep 1, 2017 | Medical University of Gdansk, Poznan University |
Organizations
Research & Development (68)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Sao Paulo | Academic/Hospital | 5 | 5 | 1 | 2011 |
| University of Toronto | Academic/Hospital | 5 | 5 | 2 | 2005 |
| Canadian Institutes of Health Research (CIHR) | Academic/Hospital | 3 | 0 | 1 | 2015 |
| Gdansk University of Physical Education and Sport | Academic/Hospital | 3 | 3 | 2 | 2016 |
| McMaster University | Academic/Hospital | 3 | 3 | 1 | 2015 |
| Medical University of Gdansk | Academic/Hospital | 3 | 0 | 1 | 2016 |
| Texas A&M University | Academic/Hospital | 3 | 3 | 1 | 2008 |
| University of Florida | Academic/Hospital | 3 | 3 | 2 | 2008 |
| Maastricht University | Academic/Hospital | 2 | 2 | 2 | 2007 |
| National Institute of Mental Health (NIMH) | Government | 2 | 0 | 2 | 2018 |
| National Institutes of Health (NIH) | Government | 2 | 0 | 2 | 2008 |
| NuSirt Biopharma | For profit | 2 | 2 | 1 | 2015 |
| Poznan University | Academic/Hospital | 2 | 2 | 1 | 2017 |
| University of Barcelona | Academic/Hospital | 2 | 2 | 1 | 2009 |
| University of Bern | Academic/Hospital | 2 | 2 | 1 | 2014 |
| University of Illinois | Academic/Hospital | 2 | 2 | 1 | 2016 |
| University of Nottingham | Academic/Hospital | 2 | 2 | 1 | 2013 |
| University of Texas, Galveston | Academic/Hospital | 2 | 2 | 2 | 2009 |
| Aarhus University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Abiogen Pharma | For profit | 1 | 0 | 1 | 2021 |